High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.

High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Abstract Text:

Igor A Schepetkin,Liliya N Kirpotina,Andrei I Khlebnikov,Mark T Quinn,

We screened a chemolibrary of drug-like molecules for their ability to activate reactive oxygen species (ROS) production in murine phagocytes, and we identified 26 novel compounds with potent neutrophil activating properties. We used substructure screening, fragment-focusing, and structure-activity relationship analyses to further probe the parent library and defined at least two groups of activators of ROS production in murine neutrophils: t-butyl benzene and thiophene-2-amide-3-carboxylic ester derivatives. Further studies of the active compounds revealed 11 compounds that activated ROS production in human neutrophils, and six of these compounds also activated intercellular Ca(2+) mobilization and chemotaxis in human neutrophils. Of the latter compounds, compound 14 (1,3-benzodioxolane-5-carboxylic acid 4'-benzyloxy-3'-methoxybenzylidene-hydrazide) activated neutrophils at nanomolar concentrations, and Ca(2+) mobilization was inhibited by pertussis toxin and N-t-butoxycarbonyl-Phe-Leu-Phe-Leu-Phe (Boc-2), an antagonist of formyl peptide receptors (FPR/FPRL1). Likewise, activation by compound 14 was desensitized after N-formyl-Met-Leu-Phe pretreatment. Similar biological activities were found for compound 104 (1,3-benzodioxolane-5-carboxylic acid 3'-bromo-5'-ethoxy-4'-hydroxybenzylidene-hydrazide), an analog of compound 14. Furthermore, conformational analysis of the activators of chemotaxis and Ca(2+) mobilization showed a high degree of similarity in distances between pharmacophore points of compounds 14 and 104 with a model of FPR published by Edwards et al. (Mol Pharmacol 68:1301-1310, 2005), indicating that conformational features of the agonists identified here are structurally compatible with steric constraints of the ligand-binding pocket of the receptor. Based on these results, we conclude that compounds 14 and 104 represent novel small-molecule agonists of FPR. These studies enhance our understanding of FPR ligand/receptor interactions and structure/activity relationships of phagocyte agonists.

High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Publishing Authors By Initials

IA Schepetkin,LN Kirpotina,AI Khlebnikov,MT Quinn,

For similar biochemical phenomena, metabolism, and nutrition: biochemical phenomena: structure-activity relationship research abstracts see: biochemical phenomena, metabolism, and nutrition: biochemical phenomena: structure-activity relationship research

PUBMED ID PMID:

MEDLINE DATE:

High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Molecular pharmacology

VOLUME: 71

Page Numbers: 1061-74

Journal Abbreviation: Mol. Pharmacol.

ISSN: 0026-895X

DAY: 17

MONTH: 01

YEAR: 2007

High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 35623

High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Keywords Mesh Terms:

KEYWORDS: Structure-Activity Relationship

MESH TERMS: agonists

Chemical & Substance for Abstract: High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Information

Substance Name: Receptors, Formyl Peptide

Registry Number: 0

Grant and Affiliation Information for High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.

AFFILIATION: Department of Veterinary Molecular Biology, Montana State University, Bozeman, Montana 59717, USA.

Country: United States

AGENCY: United States NCRR

GRANT: RR020185

ACRONYM: RR

MEDLINETA: Mol Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists Related Publications

• A role for eyebrows in regulating the visibility of eye gaze direction.
• Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging.
• Comments on the analysis of some triacid triglyceride mixtures.
• Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview.
• Contact Lenses in Pediatrics (CLIP) Study: chair time and ocular health.
• Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm.
• Gender and cleaner production: toward a framework for including gender analysis when developing strategies and designing solutions.
• Generation of a transgenic model to address regulation and function of the human neurokinin 1 receptor (NK1R).
• High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.
• Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems.
• Infants' sensitivity to uniform connectedness as a cue for perceptual organization.
• Melanoma imaging with pretargeted bivalent bacteriophage.
• N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase.
• Nitric oxide-NGF mediated PPTA/SP, ADNP, and VIP expression in the peripheral nervous system.
• Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro.
• Passivating protein coatings for implantable glucose sensors: evaluation of protein retention.
• Pharmacological treatment of heart failure.
• Reducing health disparities in depressive disorders outcomes between non-Hispanic Whites and ethnic minorities: a call for pragmatic strategies over the life course.
• Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.
• Retinopathy of prematurity in Brazil: an emerging problem.
• Review: advance provision of emergency contraception increases its use but does not reduce unplanned pregnancies.
• Role of NF-kappaB in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor-alpha.
• Spina bifida advocacy--a case study in public policy success.
• Systemic reaction rates to field stings among imported fire ant-sensitive patients receiving >3 years of immunotherapy versus <3 years of immunotherapy.
• The future in advanced prostate cancer: take your partners or is the last dance for me?
• The purification and specificity of a lipase fromVernonia anthelmintica seed.
• Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model.
• Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village.
• Trench entrapment: is ketamine safe to use for sedation in head injury?
• Uterine innervation in fibroids: a qualitative study.